TPP Global Development Ltd enters into an agreement with the University of Aberdeen for future drug

TPP Global Development Ltd (TPP) has announced an agreement with the University of Aberdeen to collaborate on the development of novel pre-clinical intellectual property originated within the University.

TPP and the University of Aberdeen will focus on commercialisation opportunities in the areas of nervous system disorders, immunology/inflammation and oncology. Initially the agreement shall run for five years, after which it may be extended.

Peter Trill, TPP’s CFO commented, “We are delighted to have entered into this agreement with the University of Aberdeen given their strong track record of academic excellence in life sciences research.”

Dr Iain Greig, Head of Operations for the Kosterlitz Centre for Therapeutics at the University of Aberdeen said, “TPP have put together a team with exactly the sort of specialist industrial experience that will complement our own strengths.  This collaboration will be of enormous value in taking forward the biomedical discoveries made at the University of Aberdeen’s Kosterlitz Centre.”

Professor Ruth Ross, Director of the Kosterlitz Centre said “The University has an international reputation for research excellence in a number of areas including pharmacology, microbiology, neurobiology and imaging.  The agreement with TPP will provide us with a mechanism whereby we can convert our discoveries into valuable new medicines of the future.”

Dr Ann Lewendon of Research & Innovation added “This agreement validates the University’s decision to set up the Kosterlitz Centre for Therapeutics.  We are delighted that TPP have come to us as the first outcome from this initiative.”

TPP has an experienced board with strong industry expertise. CEO Tom Brown and CFO Peter Trill have almost 25 years combined experience of advising on and investing in healthcare and biotech companies. Other board members include Professor Michael Walker, CEO of Verona and a founder of Rhythm Search Developments (RSD) which evolved into Nortran Pharmaceuticals and subsequently NASDAQ-listed Cardiome, and Dr Sharon O’Kane, a founder of LSE-listed Renovo.

The TPP scientific advisory board (SAB) comprises a team of exceptional scientists, chaired by Professor Sid Gilman, previously member and chairman of the FDA’s PNS/CNS committee (the panel advising the FDA on drugs targeting nervous system disorders) and a renowned scientist in the fields of Alzheimer’s and Parkinson’s diseases and other movement disorders.